The spread of antibiotic resistant bacteria is a global threat that shakes the foundations of modern healthcare. β-Lactamases are enzymes that confer resistance to β-lactam antibiotics in bacteria and there is a critical need for new inhibitors of these enzymes for combination therapy together with an antibiotic. With this in mind, we have screened a library of 490 fragments to identify starting points for the development of new inhibitors of the class D β-lactamase oxacillinase-48 (OXA-48), through Surface Plasmon Resonance (SPR), dose-rate inhibition assays and X-ray crystallography. Furthermore, we have uncovered structure-activity relationships and used alternate conformations from a crystallographic structure to grow a fragment into a more potent compound with a KD of 50 M and an IC50 of 18 M.
Introduction
Each year infections with antibiotic resistant bacteria cause an estimated 25 000 deaths in Europe. 1 Thus there is a pressing need for new strategies to treat such infections. Today, the most commonly used antibiotics are β-lactam antibiotics such as penicillins, cephalosporins and carbapenems. However, there have not been any major developments since the introduction of carbapenems in 1976, 2 and many bacteria have become resistant to virtually all β-lactam antibiotics. A major resistance mechanism to β-lactam antibiotics is the expression of β-lactamases, enzymes able to hydrolyze the β-lactam ring, which renders the drug inactive.
A prevalent β-lactamase which has caused outbreaks of antibiotic resistant bacteria all over the world is OXA-48, an oxacillinase belonging to the Ambler class D of β-lactamases.
3,4 β-
Lactamases belonging to this group have a serine in the active site similarly to the class A and C β-lactamases, 5 but show distinct properties such as dimerization 6 and a carboxylated lysine in the active site. 7 The carboxylated lysine is believed to play an important role in the β-lactam hydrolyze by acting as the general base responsible for activating the nucleophilic hydroxyl-group of the catalytic serine as well as activating the water responsible for deacetylating the complex. 8 The hydrophobic environment in the interior of the protein stabilizes the carboxylated lysine, but the pH has to be close to neutral or higher for the lysine to be non-protonated and amenable to carboxylation. 7 Without the carboxylation of the lysine there is a significant decrease in activity, and the decarboxylated enzyme appears to be inhibited by chloride ions. 7 OXA-48 is able to hydrolyze a wide range of antibiotics like penicillins and carbapenems, but is less efficient against expanded-spectrum cephalosporins. 3 The co-administration of β-lactamase inhibitors together with β-lactam antibiotics has been a successful strategy to overcome resistance caused by class A and C β-lactamases. 9 The recent approval of avibactam, a non β-lactam β-lactamase inhibitor binding covalently to the active site serine, showed that this strategy is also successful for class D β-lactamases.
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However, reports of avibactam-resistance for class A and C β-lactamases have been published [14] [15] [16] and even though no avibactam-resistance for OXA-48 has been reported yet, there is a clear need for novel β-lactamase inhibitors as additional treatment method when resistance arises.
Fragment based drug discovery (FBDD) has been a successful approach in generating drug leads for several now marketed drugs. 17 In FBDD, a set of so-called fragments, small molecules with favorable physicochemical properties and a molecular weight below 300 Da, is screened. Generally, the affinity of fragment hits is low compared to hits from traditional high-throughput screenings. Hence, fragment hits have to be further optimized into potent inhibitors by linking, evolving or growing. 18 An additional advantage of FBDD is that derivatives and analogous compounds are often commercially available, enabling rapid determination of structure-activity relationships. 19 Surface plasmon resonance (SPR)-based biosensor assays allow direct measurements of protein-ligand interactions. Furthermore, they are a useful tool to characterize such interactions by determining the kinetic parameters and the affinity. 19 SPR-based methods are also easily automated and the consumption of both protein and ligand is low. 20 Hence, SPR based assay are widely used in drug discovery to screen fragment libraries. A common challenge in FBDD are Pan-Assay Interference compounds (PAINS) that causes interference across different targets while being unlikely to progress into a potent and selective compound. 21 SPR-based assays are suitable to identify promiscuous binders and hence can avoid problems caused by PAINS. By using an orthogonal screening strategy, such as combining a biochemical assay together with an SPR assay, it is possible to identify likely PAINS. 20, 22, 23 In this study, we report the results of screening a library of 490 fragments using SPR as the primary assay. Fragment hits from this primary screen were confirmed in a secondary biochemical enzymatic assay using the substrate nitrocefin. Furthermore, for several of the identified fragments, the crystal structure in complex with OXA-48 was determined. One of the fragments was further optimized into an inhibitor with increased potency.
Results and discussion
Cloning, protein expression and purification of His-TEV OXA-48
Two different OXA-48 gene constructs were used throughout this study. The first construct, referred to as nOXA-48, was expressed with the native signal sequence and purified from the periplasm as previously described. 24 In order to increase the yield of OXA-48, a second gene construct was designed and expressed, and is henceforth referred to as tOXA-48. In this construct, the signal peptide (residues 1-22) as predicted by SignalP 25 was removed and a His-tag and a Tobacco Etch Virus (TEV) cleavage site were added. The tOXA48 construct was cloned and expressed in Escherichia coli. The protein was purified using the His-tag. The incorporation of a TEV cleavage site allowed for removal of the His-tag by TEV protease, leaving only one additional alanine at the N-terminus of tOXA-48. A second purification step separated cleaved protein from the uncleaved protein, followed by polishing by cation exchange chromatography. As judged by SDS PAGE analysis the protein was purified to homogeneity.
Expression of tOXA-48 yielded approximately 10 mg of protein per liter of culture.
Furthermore, the use of autoinduction-media reduced the hands-on time during expression since there was no need to monitor the optical density prior to induction.
Enzyme characterization and DMSO tolerance of nOXA-48
Analysis of the kinetic parameters of nOXA-48 with five β-lactam substrates and two reporter substrates (Table 1) show that nOXA-48 is able to hydrolyze carbapenems and penicillins. There has been several reports with steady-state kinetics for OXA-48, 26, 27 and our results mirror the overall trends. The penicillins are quickly hydrolyzed, while the cephalosporins cefepime and CENTA are poorly hydrolyzed. nOXA-48 is less active against the carbapenems than against the penicillins. An exception is that nOXA-48 is very active against the cephalosporin substrate nitrocefin. However, nitrocefin is known to be easily hydrolysable due to its conjugated ringsystems. 28 For nOXA-48, the kinetic parameters were determined for the hydrolyzation of nitrocefin. The determined kcat and Km were similar to the values determined for tOXA-48, indicating that there were no significant differences in enzyme activity for the two different gene constructs nOXA-48 and tOXA-48.
Nitrocefin and CENTA are common reporter substrates to monitor the activity of β -lactamases. As nitrocefin is expensive and not stable in aqueous solutions, CENTA has been recommended for its favorable chemical properties and lower price. 29 However, our comparison (Table 1) shows that nOXA-48 is most efficient against nitrocefin, and that higher concentration of the CENTA substrate were necessary for detection, limiting the sensitivity of the assay. Hence, it was decided to use inhibition assay based on nitrocefin for the following fragment screening.
Since all fragments were solved in DMSO, it was necessary to investigate the influence of DMSO on the activity of nOXA-48. In our hands, nOXA-48 was tolerated up to 2.5% DMSO without significant loss in activity towards the hydrolysis of nitrocefin (data not shown).
Dilution-series for the β-lactamase inhibitor avibactam showed 50% inhibition at 1. To verify the enzyme integrity on the chip, the interaction with the substrate meropenem was investigated ( Figure 1 ). Meropenem clearly bound to the enzyme showing that the enzyme retains activity after immobilization. However, the substrate release was very slow. Based on the report of oxacillinases dependence on bicarbonate 7 we hypothesized that the absence of bicarbonate in the running buffer leads to a decarboxylation of Lys73 causing the slow dissociation of the substrate. By including 50 mM bicarbonate (NaHCO3) in the running buffer the rate of disassociation increased dramatically as shown in Figure 1 . This indicates that adding bicarbonate to the buffer is essential to maintain the enzyme active through a carboxylated Lys73.
With bicarbonate included in the running buffer, we were able to determine the affinity and kinetic parameters for meropenem using a 1:1 binding model Figure 1 yielding 19, 22 and were therefore rejected.
The SPR based assay only identifies binders and in order to determine whether the binders were inhibitors, we performed a secondary screening for all the 77 binders using a biochemical inhibition assay against nitrocefin using nOXA-48. We were able to determine Overall there is a good agreement between the affinities (KD) measured by SPR and the IC50 values determined from the biochemical assay (Table 2) , except for compounds 8 and 9
which had higher IC50 values than expected from the KD values. There were differences in the buffers that may explain the differences. We kept the buffer for the biochemical assay identical to the kinetics buffer, except for the addition of 2.5% DMSO. Whereas for the SPR assay, we prioritized having the conditions similar to the crystallization conditions to increase the probability of obtaining X-ray crystallographic complex-structures of hits.
Ligand efficiency (LE) is a simple parameter for hit assessment, which scales the affinity with the number of non-hydrogen atoms to overcome the bias towards ligands of high molecular weight. 32 Overall, the identified hits had good affinities (Table 2) , and the calculated LE-values are within the range of what is expected of fragment-hits. 33 In summary, the ten fragments are all interesting starting points for further inhibitor development after the screening. PDBeFold at EBI (http://www.ebi.ac.uk/msd-srv/ssm). 34 The low RMSD between our tOXA-48 and the apo nOXA-48 27 indicate very similar structures, and that our structures equally well describe the OXA-48 drug target. Refinement statistics are summarized in Table 4 . Our new tOXA-48 structures all have carboxylated Lys73 residues (Kcx73) similar to e.g. nOXA-48 (PDB ID: 3HBR) as one would expect with the neutral pH. 27 All the compounds are anchored near the active site Ser70, which explains the competitive inhibition mode of these fragments.
From the crystal structure complexes of tOXA-48 and compounds 1, 2 and 3, it is clear that the carboxylate groups have ionic interactions with the sidechain of Arg250 and a charge induced hydrogen bond to sidechain oxygen of Thr209. This is consistent with the role Arg250 has in substrate binding, 35, 36 and similar to the interaction between the negatively charged sulfate group of avibactam to Arg250 in nOXA-48 (PDB ID: 4WMC) and the equivalent Arg261 in OXA-24 (PDB ID:4WM9). 12, 37 All the ten hits (compounds 1-10) are carboxylates, and since the SPR and IC50 experiments are performed at pH 7.0, the compounds are all likely to be negatively charged. The removal of the carboxylate group abolished binding, as seen for compound 11, which had no activity. Compound 14, which has a ketone functionality instead of the carboxylate group, also showed weak inhibition (Table   3 ). This shows that the carboxyl group forms interactions crucial for the fragment binding. There is no significant difference in activity between compound 1, 2 and 3 (Table 2) .
Furthermore, compound 12 ( Table 3 ) also shows that the nitrogen on the pyridine-ring is not critical for activity; while the nitrogen is useful to maintain solubility. This gives an indication that the pyridine/thiazole ring may be modified.
To investigate if the pyridine/thiazole ring was necessary for binding, as it was not clear which interactions the second ring made, compound 15 and 16 were both tested and gave very weak inhibition (Table 3) . This shows that while we could modify the pyridine/thiazole ring without losing activity, it is not beneficial to remove them. However, the addition of an amine group in compound 13 did not significantly alter the activity, which shows that the second ring may have good exit vectors.
Compounds 5-9 contain indol-or quinoline moieties as a common feature. Among these, compound 5 and 6 have the highest potency, but the LE is higher for compounds 7, 8 and 9.
Unfortunately, no clear density could be observed for these compounds in soakingexperiments, indicating that the binding mode is too flexible to be observed by X-ray crystallography.
Hit-optimization by organic synthesis
In the crystal structure of compound 1 bound to tOXA-48 we found two different fragment conformations as illustrated in Figure 4A and Figure 4B . By structurally merging the two different conformations of the pyridine ring, compound 17 was designed. Docking using GLIDE indicated that compound was able to bind to the enzyme with higher affinity as compared to compound 1, and decided to pursue the synthesis of compound 17 based on these results. A Suzuki coupling of 3,5-dibromobenzoic acid with 4-pyridylboronic acid provided compound 17 (Scheme 1) in excellent yield (96%) and good purity (>99%) as determined by HPLC analysis.
The SPR based assay was used to determine the KD of 50 µM ( Figure 5) , with a LE of 0.29 kcal per mole per heavy atom, and the enzyme inhibition assay was used to determine the IC50 of 18 µM for compound 17.
The crystal structure of compound 17 bound to tOXA-48 (tOXA-48:17; Figure 5D ) shows that it overlaps with two of the conformations observed for compound 1, which validated our approach of merging alternate conformations. Compound 17 forms hydrophobic interactions with Ser70, Ile102, Val120, Tyr211, Ser244 and Leu247, and there is an additional watermediated (W3) hydrogen bond to Arg214. This water-network was not observed for the other compounds, but this could be due to the lower resolution of these structures. Compound 17
forms ionic bonds to Arg250 ((d(Oligand…NR250) = 2.8-2.9 Å), and water-mediated hydrogen bonds to both Ser118 (W1) and Thr209 (W2) and with an intricate water-network revealed by the high resolution of this structure.
There is still a need to investigate the possible exit vectors of compound 17, however compound 17 shows that for this class of compounds it is possible to optimize inhibitor propensity in terms of higher enzyme affinity and demonstrates that alternate conformations may be used as a tool in structure guided drug design.
Based on a sequence alignment of the class D β-lactamase family 38 it is reasonable to believe that compound 17 would have potential to inhibit the majority of the family. Ala69, Trp105, Val120, Leu158, Thr209 and Arg250 are all conserved (>80% of the family-members), and in many of the cases the amino acid substitutions might be compatible with the same interactions.
It is interesting to compare the results of this study with the inhibitor scaffolds identified for the Ambler class B metallo-β-lactamase VIM-2 3,4 from similar experiments. 39 Several of the hits overlap and more than half of the hits identified are carboxylates. While there is no significant sequence identity between the different classes of β-lactamases, both enzymes OXA-48 and VIM-2 are capable of hydrolyzing the same substrates, and could potentially be inhibited by the same compounds. Incidentally, compound 17 also shows some activity against VIM-2 (data not shown), opening the possibility of a pan β-lactamase inhibitor.
Conclusions
In this study, we have done a fragment screening for new inhibitor scaffolds of the class D β- 
Experimental Section
General procedures: As long as not otherwise stated chemicals were purchased from SigmaAldrich, and used as received. Compound 13 were purchased from Fluorochem (UK) and compound 14 from Enamine (USA). All chemicals were of analytical quality. Residues are numbered according to the apo OXA-48 structure (PDB ID:3HBR).
Cloning, protein expression and purification of His-TEV OXA-48(tOXA-48)
Native full-length OXA-48 with the native leader sequence was expressed and purified from the periplasm as previously described, 24 and is referred to as nOXA-48.
In addition, a new His-TEV OXA-48 gene construct was cloned by introducing a hexahistidine tag together with a TEV protease cleavage site while removing the predicted native leader sequence (residues 1-22) from SignalP. 25 This construct is henceforth called tOXA-48.
The cloning was done similarly to the native full-length OXA-48 using exponential megapriming PCR cloning, 24, 40 however, the insertion of the TEV protease site required multi-component assembly. 41 All primers (Sigma-Aldrich, Table 5 ) were desalted and dissolved to 100 µM in nuclease-free water.
The new tOXA-48 construct was transformed into in house modified E. coli strain BL21 Star 
Fragment library
490 fragments were purchased from the Maybridge Ro3 collection. All compounds were dissolved in 100% DMSO to a concentration of 150 mM. These stock liquids and powders were kept at 4 °C, while aliquot samples were kept at -20 °C. All fragments in the library had a molecular weight between 80 and 300 Da, a cLogP ≤ 3, the number of H-bond acceptors and donors was ≤ 3 and the number of rotatable bonds was ≤ 3.
Biochemical studies: enzyme kinetics, DMSO tolerance and inhibition studies
All experiments were performed using a Spectramax M2e at 25 °C. Initial velocities were determined in the SoftMax Pro software (Molecular Devices). All experiments were done with a volume of 100 µL.
Michaelis-Menten kinetics were first established for the chromogenic β-lactam substrate nitrocefin in the kinetics buffer with 100 mM Na2HPO4/NaH2PO4 (pH 7.0), 50 mM NaHCO3 and 0.2 mg/ml BSA as previously described. 26 Then additional substrates were examined: (GraphPad Software) to determine the IC50-value. The Hill-constant was kept constant at 1.
Surface plasmon resonance (SPR) interaction studies: primary screening and KD measurements
All SPR experiments were performed on a Biacore T200 at 25°C. The data were analyzed using Biacore T200 Evaluation Software 2.0 (GE Healthcare). The sensorgrams were double reference subtracted using a reference surface and blank injections.
tOXA-48 was diluted to 25 µg/mL in 10 mM MES pH 5.5. The enzyme was immobilized to a level of around 5000 RU on a CM5-chip using standard amine coupling. Positive controls (meropenem) were tested every 12 th cycle to ensure active enzyme together with blanks (running buffer), and solvent-correction with a DMSO-gradient (1.5-4%) was performed every 48 th cycle. Seven startup cycles with running buffer were performed. No surface regeneration was done, and protein was immobilized to a new flow-channel when the ratio of the response to control surface was significantly lowered.
For testing fragments in concentration series, they were tested in a dilution-series with six concentrations from 118-900 µM. Seven startup cycles with buffer were performed. A positive control (meropenem) was used for every 30 th cycle and a negative control with buffer was used for every 30 th cycle. Solvent correction with varying DMSO concentration was performed every 45 th cycle. Affinities were calculated from the steady-state affinity model with a constant Rmax adjusted by the control and molecular weight of the fragment.
The same protocol was used for the compounds 11-17, with the exception that compound 17 had 10 dilutions with concentrations from 1.8-900 µM.
Crystallization, soaking and X-ray data collection
Crystals of tOXA-48 were obtained by vapor diffusion technique in a manual hanging drop setup. tOXA-48 at 8 mg/mL was mixed with reservoir solution containing 0.1 M HEPES pH 7.5, 10% PEG 8000 and 4-8% 1-butanol as previously published 12 with a drop-ratio of 1.5:2.5 µL for protein:reservoir.
Fragments were diluted to 3.75 mM in the cryo solution with 0.1 M HEPES pH 7.5, 10%
PEG 8000, 5% 1-butanol and 25% ethanediol and crystals were soaked for two hours (OXA- X-ray diffraction data were collected at the BL 14.1 and 14.2 beamlines at BESSY (Berlin, Germany). The data was integrated in XDS. 43 The datasets were scaled and merged in AIMLESS. 44 Molecular replacement was performed with PHASER 45 with the nOXA-48 apo structure (PDB ID: 3HBR) 27 as search model to obtain initial phases.
Electron density could be seen for three fragments and compound 17 after initial refinement in PHENIX 46 when automatically added waters were removed from the active site and the difference Fourier electron density maps recalculated. Restraints for the fragments were prepared using the GRADE webserver, 47 the fragments were placed manually using COOT, 48 and the final refinements were done in PHENIX. Omit-maps were calculated using the phenix.polder-tool. 46, 49 Figures were made using PyMOL 50 and LigPlot+
51
.
Docking of compound 17
The structure of tOXA-48:1 was used as a starting model. The protein preparation wizard in
Maestro was used to add hydrogens, assign bond orders, delete waters and optimize the hydrogen bond network. A docking grid was prepared using the coordinates of compound 1 as the centroid. Compound 17 was prepared using the Ligprep tool to generate 3D
coordinates, optimize geometries and assign ionization states. Compound 17 was docked using the induced fit protocol 52 in the Schrödinger suite 2013-1 with no constrains defined and with residues within 5 Å of the binding pose refined.
Organic synthesis of compound 17
Compound 17 was prepared in analogy to literature (Scheme 1). 53 3,5-Dibromobenzoic acid (228 mg, 0.81 mmol, 1 equiv), 4-pyridylboronic acid (300 mg, 2.4 mmol, 3 equiv) and potassium phosphate (1.04 g, 4.9 mmol, 6 equiv) were dissolved in dioxane (6 mL) and water 
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Figure S1 HPLC analysis of compound 17 after synthesis confirms the purity of the compound to be 99.7%.
Figure S2
Enzyme kinetic steady-state plots for nOXA-48 with penicillins, one cephalosporin, carbapenems and reporter substrates. Steady state plot of tOXA-48 with the reporter substrate nitrocefin is also shown.
S4
Figure S3 Sensorgrams (left panels) and steady-state plots (middle panels) for the binding of compounds 12 and 13 binding to tOXA-48. 2-fold dilution series from (118-900 µM) were used to determine the KD. Steady state values were plotted against the concentration. The data were fitted to 1:1 interaction model and the KD was calculated. IC50-plots (right panels) of compounds 12 and 13 inhibiting nitrocefin breakdown by nOXA-48, based on non-linearregression analysis. The determined IC50 values are indicated for both compounds. 
